Korean J Med.  1998 May;54(5):607-614.

Postoperative Sequential Mitomycin-C, Vinblastine, and Cisplatin (MVP) Chemotherapy and Radiotherapy for Resected Stage II-IIIA Non-small Cell Lung Cancer

• Kim TW
• Lee JS
• Jung BH
• Yun HJ
• Zang DY
• Lee JH
• Kim SB
• Kim SW
• Suh C
• Lee KH
• Kim WK
• Kim WD
• Kim JH
• Choi EK
• Chang H
• Kim DK
• Park SI
• Sohn KH
• Kim SH

Abstract

OBJECTIVES
The poor survival rates among patients receiving surgery alone for stages II and III non-small cell lung cancer prompted several trials of adjuvant therapy after resection. We performed a prospective phase II study in patients with stage II-IIIA non-small cell lung cancer after resection to evaluate the feasibility, activity and toxicity of the postoperative sequential MVP chemotherapy and radiotherapy.
METHODS
Between February 1991 and May 1995, 60 patients with resected stage II, IIIA non-small cell lung cancer received 2 cycles of MVP combination chemotherapy (Mitomycin-C 6 mg/m2, Vinblastine 6 mg/m2, Cisplatin 60 mg/m2) within 3 weeks after surgery, followed by thoracic irradiation (5,040 cGy after complete resection and 900 cGy booster to microscopically positive resection margin at 1.8 Gy per fraction) within 3-4 weeks after chemotherapy.
RESULTS
Forty nine men and 11 women with a median age of 60.5 years (range 33-81 years) were included. During the median follow-up period of 828 days (61-2,015 days), 25 patients had developed recurrence. Among the 25 failures, 3 were local relapse only and 20 were distant metastasis only and 2 had both local and distant sites of recurrence. Three-year overall survival and event-free survival were 43% and 37%, respectively. Neutropenia of grade I-II was observed only in 13 patients. Eleven patient showed grade I-II radiation pneumonitis and 32 had grade I-II radiation esophagitis.
CONCLUSION
Postoperative sequential MVP chemotherapy and radiotherapy in resected stage II-IIIA non-small cell lung cancer is well-tolerated and shows interesting activity.

Keyword

Non-small cell lung cancer; Postoperative chemotherapy; Postoperative radiotherapy

MeSH Terms

Carcinoma, Non-Small-Cell Lung*
Cisplatin*
Disease-Free Survival
Drug Therapy*
Drug Therapy, Combination
Esophagitis
Female
Follow-Up Studies
Humans
Male
Mitomycin*
Neoplasm Metastasis
Neutropenia
Prospective Studies
Radiation Pneumonitis
Radiotherapy*
Recurrence
Survival Rate
Vinblastine*
Cisplatin
Mitomycin
Vinblastine